What McKesson's latest 10-Q says: 9 signals
McKesson filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses acquisition completed, capex increase and cash flow concern.
Public (MCK)Hospitals and Health Care10,000+ employeesmckesson.comLinkedIn
- Filed
- Aug 5, 2026
- Filings
- 2
- Signals
- 20
10-Q · latest 10
What McKesson's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 9 signals
McKesson's Medical-Surgical unit secures $4.45B in new capital for strategic initiatives.
The Medical-Surgical Solutions segment raised $3.2B in new term loans and received a $1.25B investment from Apollo Funds in Q1 FY2027.
$4.5B
New debt ($3.2B) and equity capital ($1.25B) for the Medical-Surgical Solutions segment.
13%
Approximate interest in Medical-Surgical Solutions acquired by Apollo Funds.
Apollo FundsJPMorgan Chase Bank, N.A.
McKesson's Medical-Surgical unit secures $3.2B in new term loans to fuel segment
The Medical-Surgical Solutions segment entered into new credit agreements for $3.2 billion, indicating a major capital infusion that will likely fund strategic initiatives, technology upgrades, or operational changes within that specific business unit.
$3.2B
Total proceeds from new senior secured term loans for the Medical-Surgical Solutions segment
McKesson spent $152M in Q1 CapEx, including investments in capitalized software.
The company's $152 million in capital expenditures for the quarter includes spending on capitalized software, indicating ongoing budget and projects related to technology infrastructure and enterprise applications.
$152M
Capital expenditures for property, plant, equipment, and capitalized software.
McKesson flags rising inventory and receivables as a key working capital challenge.
The company reported an increase in both inventory and receivables, tying up cash and increasing pressure on its working capital.
McKesson faces $5.7B total estimated liability from opioid-related claims
The company has a total estimated litigation liability of $5.7 billion for opioid-related claims, creating significant financial pressure to optimize costs, improve operational efficiency, and enhance compliance and reporting systems across the organization.
$5.7B
Total estimated litigation liability for opioid-related claims as of June 30, 2026
McKesson continues to digest its acquisition of Core Ventures, funded by a $2.0B debt offering
Although the acquisition of Core Ventures was completed in the prior fiscal year, large-scale integrations create ongoing needs for system consolidation, process harmonization, and data migration.
$2B
Debt proceeds used to fund the purchase of Core Ventures.
Working capital increases due to rising receivables and inventory levels
McKesson's working capital increased due to higher receivables and inventory, suggesting potential challenges in its cash conversion cycle.
- SEC EDGAR
10-Q
Filed · 11 signals
CEO Brian S. Tyler adopts trading plan to sell up to 48,657 shares, effective Dec 15, 2025.
Rule 10b5-1
McKesson carries a $5.7 billion estimated litigation liability for opioid-related claims.
This massive, ongoing liability creates significant financial pressure and a need for robust legal, compliance, and financial management systems to handle complex payment schedules and reporting requirements.
$5.7B
Total estimated litigation liability for opioid-related claims
The acquisition of a 70% stake in Core Ventures is a significant transaction that will require substantial post-merger integration efforts across IT, finance, and operations.
$700M
Redeemable noncontrolling interests related to the acquisition of 70% of Core Ventures
Showing 10 of 20 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
McKesson earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Investing heavily in distribution center automation and robotics.Management is strategically allocating capital to scale automation, including robotics, in its distribution centers to improve productivity and efficiency. This creates opportunities for vendors specializing in logistics technology, robotics, and process optimization. | |
| Integrating major acquisitions in oncology and ophthalmology, spending $3.4BMcKesson recently spent $3.4 billion to acquire Core Ventures (Florida Cancer Specialists) and PRISM Vision. Active integration efforts are underway, creating needs for practice management software, EHR integration, data analytics, and administrative services to merge these large provider networks onto McKesson's platforms. | |
| Investing heavily in warehouse automation, robotics, and facility modernizationMcKesson is actively modernizing its distribution network with automated storage/retrieval systems, picking systems, and mobile autonomous robots (cobots) to improve productivity, quality, and safety. This creates significant opportunities for vendors specializing in warehouse automation, robotics, and supply chain technology. | |
| Actively implementing artificial intelligence to drive operating leverage.The CFO explicitly stated the company is using AI to deliver efficiency and operating leverage. This signals a clear budget and strategic focus on adopting AI solutions across the enterprise, presenting an opening for AI technology and service providers. | |
| Announced a $2.5 billion share repurchase plan for the fiscal year.This massive capital return program highlights the company's extremely strong cash flow and financial position. A company with this level of excess capital has significant budget flexibility for strategic operational and technology investments. | |
| Prioritizing AI and advanced technology to drive operating leverage and efficiencyThe CFO highlighted the use of Artificial Intelligence and advanced technologies as key drivers for improving the company's operating expense ratio. This C-level focus on AI for cost discipline signals budget and receptiveness for AI-powered solutions that can deliver measurable efficiency gains across the enterprise. |
Signal API · MCP
Track McKesson with the Signal API
One POST /v1/companies/enrich call with mckesson.com returns McKesson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"mckesson.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about McKesson 10-Q
When did McKesson file its latest 10-Q?
What did McKesson disclose in its latest 10-Q?
What did McKesson say on its recent earnings calls?
Where can I read McKesson's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .